VG161

DB18469InvestigationalProtein Based Therapies

VG161 is an oncolytic virus therapy under investigation for the treatment of cholangiocarcinoma.

Mechanism: Pharmacologically active on Interleukin-12 subunit beta, Programmed cell death 1 ligand 1, and Interleukin-15
Curator reviewed
Code names: VG-161

Resolves to

Targets

What you can answer from here — as of July 09, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with VG161, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.